x

Posted 20 March, 2024

Cue Health Inc. appointed Clint Sever as new CEO

Nasdaq:HLTH appointed new Chief Executive Officer Clint Sever in a 8-K filed on 20 March, 2024.


  On March 20, 2024, the Company appointed co-founder and current Chief Product Officer, Clint Sever, as Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Cue Health Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.
Market Cap
$38.7M
View Company Details
Cue Health Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On March 19, 2024, Cue Health Inc. (the "Company") announced that Ayub Khattak is stepping down as Chief Executive Officer, President and Chairman of the Board, effective immediately. Mr. Khattak will remain as a member of the Board of Directors. On March 20, 2024, the Company appointed co-founder and current Chief Product Officer, Clint Sever, as Chief Executive Officer. Mr. Sever's biography can be found in the Company's proxy statement filed with the Securities and Exchange Commission on April 25, 2023. 

A copy of the related press release announcing the leadership transition and the appointment of Board advisors is attached hereto as Exhibit 99.1.